Coloplast As Stock Net Income
| CLPBF Stock | USD 75.75 4.25 5.31% |
As of the 10th of February, Coloplast A/S shows the Mean Deviation of 1.59, risk adjusted performance of (0.07), and Standard Deviation of 2.6. Coloplast A/S technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Coloplast A/S standard deviation, treynor ratio, as well as the relationship between the Treynor Ratio and potential upside to decide if Coloplast A/S is priced correctly, providing market reflects its regular price of 75.75 per share. Given that Coloplast A/S has information ratio of (0.13), we suggest you to validate Coloplast AS's prevailing market performance to make sure the company can sustain itself at a future point.
Coloplast A/S's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Coloplast A/S's valuation are provided below:Coloplast AS does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Coloplast |
Coloplast A/S 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Coloplast A/S's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Coloplast A/S.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Coloplast A/S on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Coloplast AS or generate 0.0% return on investment in Coloplast A/S over 90 days. Coloplast A/S is related to or competes with Terumo, Straumann Holding, Straumann Holding, Terumo Corp, Sartorius Stedim, Sartorius Aktiengesellscha, and Sino Biopharmaceutica. Coloplast AS engages in the development and sale of intimate healthcare products and services in Denmark, the United Sta... More
Coloplast A/S Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Coloplast A/S's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Coloplast AS upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 12.23 | |||
| Value At Risk | (5.72) | |||
| Potential Upside | 3.14 |
Coloplast A/S Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Coloplast A/S's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Coloplast A/S's standard deviation. In reality, there are many statistical measures that can use Coloplast A/S historical prices to predict the future Coloplast A/S's volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.71) |
Coloplast A/S February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.70) | |||
| Mean Deviation | 1.59 | |||
| Coefficient Of Variation | (1,044) | |||
| Standard Deviation | 2.6 | |||
| Variance | 6.74 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.71) | |||
| Maximum Drawdown | 12.23 | |||
| Value At Risk | (5.72) | |||
| Potential Upside | 3.14 | |||
| Skewness | (1.08) | |||
| Kurtosis | 2.62 |
Coloplast A/S Backtested Returns
Coloplast A/S secures Sharpe Ratio (or Efficiency) of -0.12, which signifies that the company had a -0.12 % return per unit of risk over the last 3 months. Coloplast AS exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Coloplast A/S's Risk Adjusted Performance of (0.07), mean deviation of 1.59, and Standard Deviation of 2.6 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.36, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Coloplast A/S's returns are expected to increase less than the market. However, during the bear market, the loss of holding Coloplast A/S is expected to be smaller as well. At this point, Coloplast A/S has a negative expected return of -0.3%. Please make sure to confirm Coloplast A/S's potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Coloplast A/S performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.25 |
Poor predictability
Coloplast AS has poor predictability. Overlapping area represents the amount of predictability between Coloplast A/S time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Coloplast A/S price movement. The serial correlation of 0.25 indicates that over 25.0% of current Coloplast A/S price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.25 | |
| Spearman Rank Test | -0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 8.19 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Coloplast AS reported net income of 4.71 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Medical Instruments & Supplies industry. The net income for all United States stocks is significantly lower than that of the firm.
Coloplast Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coloplast A/S's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Coloplast A/S could also be used in its relative valuation, which is a method of valuing Coloplast A/S by comparing valuation metrics of similar companies.Coloplast is currently under evaluation in net income category among its peers.
Coloplast Fundamentals
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 28.84 B | |||
| Shares Outstanding | 194.31 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 25.53 % | |||
| Price To Earning | 37.47 X | |||
| Price To Book | 22.60 X | |||
| Price To Sales | 1.15 X | |||
| Revenue | 22.58 B | |||
| Gross Profit | 15.53 B | |||
| EBITDA | 7.23 B | |||
| Net Income | 4.71 B | |||
| Cash And Equivalents | 854 M | |||
| Cash Per Share | 4.02 X | |||
| Total Debt | 16.36 B | |||
| Debt To Equity | 2.83 % | |||
| Current Ratio | 1.01 X | |||
| Book Value Per Share | 27.81 X | |||
| Cash Flow From Operations | 5.1 B | |||
| Earnings Per Share | 3.14 X | |||
| Price To Earnings To Growth | 3.41 X | |||
| Target Price | 16.42 | |||
| Number Of Employees | 14.5 K | |||
| Beta | 0.21 | |||
| Market Capitalization | 24.87 B | |||
| Total Asset | 34.96 B | |||
| Retained Earnings | 4.89 B | |||
| Working Capital | 855 M | |||
| Current Asset | 6.16 B | |||
| Current Liabilities | 5.31 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 2.05 % | |||
| Net Asset | 34.96 B | |||
| Last Dividend Paid | 20.0 |
About Coloplast A/S Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coloplast AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coloplast A/S using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coloplast AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Coloplast Pink Sheet
Coloplast A/S financial ratios help investors to determine whether Coloplast Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Coloplast with respect to the benefits of owning Coloplast A/S security.